Worth reading
66In focus
Scored from 4 of 6 sectionsDirection
Improvement
Direction inferred from the company’s description.Scale
27
% (year-on-year change in profit from ordinary operating activities)Wording
Conditional
How definitive the wording is.Contents of this document
Presentation materials for financial resultsSecond quarter of the fiscal year ending March 20277 items taken from the company’s own explanation
Financial Results Figures (The key points of this material are explained below)
Net Sales¥2,602 100 million+11.0%
Operating profit¥894 100 million +27.0%profit from ordinary operating activities
Ordinary income¥916 100 million +27.0%profit before tax, IFRS
Results for the three months of the current quarter
Revenue
¥2,602 100 million+11.0%
Profit from ordinary operating activities
¥894 100 million+27.0%
Profit before tax
¥916 100 million+27.0%
What the company explained in this material
Assumptions Underlying the Business OutlookThe assumptions used by the company in preparing its forecast.
USD/yen159.36
EUR/yen182.99
New initiatives
- Global rollout of the second-generation MiYOSMART iQ product
- Plan to roll out MiYOSMART iQ to 54 countries by the end of FY26 Q3
- Consideration of bringing forward production increases and capacity expansion at existing HDD substrate plants
- Expansion of production capacity for polarization glass (CUPO) for optical transceivers
- Validation toward realizing blanks for 12-inch large masks for High NA
Key KPIsA metric the company considers important as a management benchmark.
- ROIC26 %
- Eyeglass lens revenue growth8 %
- Contact lens (eyecity) revenue growth1 %
- Endoscope revenue growth-10 %
- Intraocular lens revenue growth5 %
- Artificial bone and other revenue growth2 %
- LSI revenue growth20 %
- FPD revenue growth21 %
- HDD substrate revenue growth32 %
- Optical Solutions Sales Growth Rate14 %
Unit price and quantity metricsThese figures show sales broken down by price and volume.
Regarding sales volume, the disclosure states that sales of 3.5-inch HDD substrates increased significantly. The combined metric for unit price and volume is Not disclosed.Segment results
- Life CareRevenue¥153.4 billion (YoY +4.0%)Profit from ordinary operating activities¥32.6 billion (YoY +26.0%)
- Information and CommunicationsRevenue¥106.8 billion (YoY +23.0%)Profit from ordinary operating activities¥58.8 billion (YoY +28.0%)
Financial targets
Actual ROIC: 26.0%. Target: Not disclosedMarket Size / Share
- Potential market for myopia management solutions (purchasing-power adjusted)3.6 bn USD
- Myopia management spectacle lens market0.5 bn USD
- Projected 2030 myopia management spectacle lens market1 bn USD
| Item | Details |
|---|---|
| Document type | Presentation materials for financial results |
| Fiscal Period Covered | Second quarter of the fiscal year ending March 2027 |
| Net Sales | ¥2,602 100 million (YoY +11.0%) |
| Operating profit | ¥894 100 million (profit from ordinary operating activities) (YoY +27.0%) |
| Ordinary income | ¥916 100 million (profit before tax, IFRS) (YoY +27.0%) |
| Results for the three months of the current quarter | Revenue ¥2,602 100 million (YoY +11.0%) / Profit from ordinary operating activities ¥894 100 million (YoY +27.0%) / Profit before tax ¥916 100 million (YoY +27.0%) |
| Segment results | Segment Life Care / Revenue ¥153.4 billion (YoY +4.0%) / Profit from ordinary operating activities ¥32.6 billion (YoY +26.0%), Segment Information and Communications / Revenue ¥106.8 billion (YoY +23.0%) / Profit from ordinary operating activities ¥58.8 billion (YoY +28.0%) |
| Key KPIs | Indicator name ROIC / Value 26 % / Year on year against the same period last year Not disclosed, Indicator name Eyeglass lens revenue growth / Value 8 % / Year on year against the same period last year Not disclosed, Indicator name Contact lens (eyecity) revenue growth / Value 1 % / Year on year against the same period last year Not disclosed, Indicator name Endoscope revenue growth / Value -10 % / Year on year against the same period last year Not disclosed, Indicator name Intraocular lens revenue growth / Value 5 % / Year on year against the same period last year Not disclosed, Indicator name Artificial bone and other revenue growth / Value 2 % / Year on year against the same period last year Not disclosed, Indicator name LSI revenue growth / Value 20 % / Year on year against the same period last year Not disclosed, Indicator name FPD revenue growth / Value 21 % / Year on year against the same period last year Not disclosed, Indicator name HDD substrate revenue growth / Value 32 % / Year on year against the same period last year Not disclosed, Indicator name Optical Solutions Sales Growth Rate / Value 14 % / Year on year against the same period last year Not disclosed |
| Unit price and quantity metrics | Regarding sales volume, the disclosure states that sales of 3.5-inch HDD substrates increased significantly. The combined metric for unit price and volume is Not disclosed. |
| Assumptions Underlying the Business Outlook | USD/yen 159.36 / EUR/yen 182.99 |
| Financial targets | Actual ROIC: 26.0%. Target: Not disclosed |
| Market Size / Share | Potential market for myopia management solutions (purchasing-power adjusted) 3.6 bn USD, Myopia management spectacle lens market 0.5 bn USD, Projected 2030 myopia management spectacle lens market 1 bn USD |
| New initiatives | Global rollout of the second-generation MiYOSMART iQ product, Plan to roll out MiYOSMART iQ to 54 countries by the end of FY26 Q3, Consideration of bringing forward production increases and capacity expansion at existing HDD substrate plants, Expansion of production capacity for polarization glass (CUPO) for optical transceivers, Validation toward realizing blanks for 12-inch large masks for High NA |
Items this document does not state (18)
Net incomeGross Profit MarginOperating profit marginSelling, general and administrative expensesFull-year earnings forecastProgress against full-year forecastSelf-assessment against the planBreakdown of Factors Affecting the ChangeNumber of stores and locationsNumber of employeesRisk amount incorporated into the outlookMedium-term management plan targetsAnnual DividendPayout ratioAcquisition of treasury sharesCapital expendituresOrders received and order backlogKey points of the Q&A
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.This was attributable to higher revenue in the Information and Communications segment, improved profit margins in the Lifecare segment, product mix and cost rationalization, and expanded sales of high-value-added products.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.